Prostate cancer and PARP inhibitors: progress and challenges

Prostate cancer and PARP inhibitors: progress and challenges

Abstract Despite survival improvements achieved over the last two decades, prostate cancer remains lethal at the metastatic castration-resistant stage (mCRPC) and new therapeutic approaches are needed. Germinal and/or somatic alterations of DNA-damage response pathway genes are found in a substantia...

Full description

Bibliographic Details
Main Authors: Diego Teyssonneau, Henri Margot, Mathilde Cabart, Mylène Anonnay, Paul Sargos, Nam-Son Vuong, Isabelle Soubeyran, Nicolas Sevenet, Guilhem Roubaud
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Journal of Hematology & Oncology
Subjects:
PARP inhibitors
Prostate cancers
Homologous recombination repair
DNA repair
Online Access:https://doi.org/10.1186/s13045-021-01061-x

Internet

https://doi.org/10.1186/s13045-021-01061-x

Similar Items